pharmaphorum

JULY 26, 2022

There was also continued decline for Tecfidera, which have not been offset by follow-up Vumerity (diroximel fumarate), which has fewer side effects. It had expected the drug would not face biosimilar competition in Europe until at least 2027. Tecfidera’s decline has made Tysabri Biogen’s top-selling drug.

Competition 52

Competition Side effects Marketing Sales 52

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. million in Q3.

Medical 105

Medical Manufacturing Insurance Side effects 105

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. million in Q3.

Medical 98

Medical Manufacturing Insurance Side effects 98